2 weeks Ago By Defense World Staff
American Century Companies Inc. raised its stake in Intellia Therapeutics, Inc. ( NASDAQ:NTLA – Free Report ) by 3.
5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 453,821 shares of the company’s stock after acquiring an additional 15,385 shares during the period. American Century Companies Inc.
owned approximately 0.45% of Intellia Therapeutics worth $5,292,000 as of its most recent SEC filing. A number of other institutional investors have also recently modified their holdings of NTLA.
Whipplewood Advisors LLC bought a new position in Intellia Therapeutics in the 4th quarter worth about $40,000. Jones Financial Companies Lllp raised its holdings in Intellia Therapeutics by 140.9% in the fourth quarter.
Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after buying an additional 2,280 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of Intellia Therapeutics by 80.
6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock worth $60,000 after buying an additional 2,299 shares in the last quarter.
KBC Group NV grew its holdings in shares of Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company’s stock valued at $71,000 after buying an additional 2,340 shares during the last quarter.
Finally, AdvisorNet Financial Inc increased its position in shares of Intellia Therapeutics by 96.4% during the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock valued at $118,000 after acquiring an additional 4,950 shares in the last quarter.
88.77% of the stock is owned by hedge funds and other institutional investors. Analyst Upgrades and Downgrades Several equities analysts recently issued reports on the company.
BMO Capital Markets lowered their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th.
Truist Financial lowered their price target on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th.
Citigroup lifted their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 28th.
Morgan Stanley cut shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th.
Finally, Oppenheimer reduced their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday, January 13th.
Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.
56. Intellia Therapeutics Stock Performance NASDAQ NTLA opened at $6.63 on Friday.
The business’s fifty day moving average is $9.61 and its 200 day moving average is $13.33.
The company has a market capitalization of $686.32 million, a PE ratio of -1.22 and a beta of 2.
23. Intellia Therapeutics, Inc. has a fifty-two week low of $6.
43 and a fifty-two week high of $28.18. Intellia Therapeutics Profile ( Free Report ) Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics.
The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. See Also Five stocks we like better than Intellia Therapeutics Stock Market Sectors: What Are They and How Many Are There? Archer Aviation’s Africa Deal Could Boost ACHR Stock 3 Small Caps With Big Return Potential Are Short Sellers Wrong About These 3 Semiconductor Stocks? What is the S&P 500 and How It is Distinct from Other Indexes Boeing Gets $50B in March Orders—Is BA Stock a Buy Now? Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc.
( NASDAQ:NTLA – Free Report ). Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
